SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totaling 9,524 shares, an increase of 1,461.3% from the June 30th total of 610 shares. Based on an average daily volume of 264,901 shares, the short-interest ratio is currently 0.0 days.
SAB Biotherapeutics Trading Down 17.1%
Shares of SABSW stock traded down $0.00 during trading hours on Friday, reaching $0.01. The company’s stock had a trading volume of 9,797 shares, compared to its average volume of 50,304. SAB Biotherapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.06. The firm’s 50 day simple moving average is $0.01 and its 200-day simple moving average is $0.02.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
See Also
- Five stocks we like better than SAB Biotherapeutics
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
